Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Obesity, Cardiovascular Disease, High Blood Pressure
Interventions: In Person, At Home; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Symptomatic Non-erosive Gastroesophageal Reflux Disease
Interventions: Vonoprazan, Placebo; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Mentor, Ohio

Conditions: Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions: Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Tafasitamab, Venetoclax; Drug · Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Diverticulitis
Interventions: Medi for All, Standard Fiber Supplementation; Behavioral · Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Carcinoma
Interventions: Spot Delete planning for proton therapy, Traditional proton treatment planning system; Radiation
Lead sponsor: Covenant Health Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Schizophrenia
Interventions: Lurasidone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Osteoarthritis, Knee
Interventions: MISHA Knee System, Non-Surgical Treatment; Device · Other
Lead sponsor: Moximed; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Davis, California • Oceanside, California • Sacramento, California + 6 more

Conditions: HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
Interventions: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker; Drug · Other
Lead sponsor: Lifespan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cranston, Rhode Island

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions: CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules; Drug · Other
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Theta Burst Stimulation; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Oropharyngeal Dysphagia
Interventions: Negative Pressure Suction Catheter; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Obesity, Insulin Resistance, Cardiovascular Risk Factor
Interventions: Exercise; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
Interventions: Discontinuation and Reinitiation of Tirzepatide; Other
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Baton Rouge, Louisiana • Cleveland, Ohio • Milwaukee, Wisconsin

Conditions: Prediabetic State
Interventions: GlucoSupreme™ Herbal, Placebo; Dietary Supplement · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Cerebral Palsy
Interventions: SAFO worn, SAFO not worn; Device · Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 2 Years to 9 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Endometrial Hyperplasia, Endometrial Hyperplasia Without Atypia
Interventions: Metformin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Southern Pines, North Carolina • Philadelphia, Pennsylvania

Conditions: Chickenpox, Herpes Zoster
Interventions: famciclovir; Drug
Lead sponsor: Novartis; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Cerebrovascular Disorders
Interventions: Antioxidant Cocktail, Placebo; Dietary Supplement · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Multiple Myeloma
Interventions: Clarithromycin, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis
Interventions: TSA with tenotomy technique, TSA with lesser tuberosity osteotomy technique, Shoulder prosthesis; Procedure · Device
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Migraine
Interventions: Erenumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 31
States / cities: Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more

Conditions: Venezuelan Equine Encephalomyelitis
Interventions: 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: Breast Cancer
Interventions: F-Var3 PET/CT, Blood draw; Diagnostic Test · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Healthy Bodies, Healthy Hearts: A Physical Activity Intervention Trial

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Investigation of Medical Management to Prevent Episodes of Diverticulitis Trial

Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement

High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

MOTION Clinical Trial

Implementing Low-Barrier HCV Treatment in a Jail Setting

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Theta Burst Stimulation for Schizophrenia

Utilization of Negative Pressure Suction to Reduce Aspiration in Oropharyngeal Dysphagia

Effects of Obesity and Intensity of Exercise on Ghrelin Levels

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting

RCT of a Polyherbal Dietary Supplement for Prediabetes

Orthotics in Ambulatory Cerebral Palsy

Metformin for the Treatment of Endometrial Hyperplasia

Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

HYPEROXIA Responses and ROS

Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

Lesser Tuberosity Osteotomy for Subscapularis Repair

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer